Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Theranostic Peptide Tracers for Breast Cancer

Project description

Theranostic peptide tracers for better breast tumour diagnosis

Breast cancer causes over half a million deaths each year. Current diagnostic methods are often inadequate. Approximately 40 % of cases have already spread by the time they are diagnosed, and mammograms frequently produce false positives. Moreover, there is a lack of reliable tools to monitor treatment response or visualise tumours during surgery. The ERC-funded Peptide Tracers project aims to develop theranostic peptide tracers that target the oxytocin receptor (OTR), a promising approach for imaging, diagnosing, and treating breast cancer. OTR is overexpressed in difficult-to-treat cases, such as metastatic and triple-negative breast cancer. Building on previously developed OTR-specific peptide tracers, the project will refine their design and demonstrate their potential to visualise breast tumours.

Objective

Breast cancer impacts one in eight women globally, resulting in over half a million deaths each year. Current diagnostic methods fall short, with ~40% of breast cancers having already spread at the time of diagnosis and mammography often producing high rates of false positives. Additionally, there is a lack of reliable tools for monitoring treatment responses, tracking recurrences, or providing real-time tumour visualisation to aid surgical tumour removal.

This project addresses these challenges by developing theranostic peptide tracers targeting the oxytocin receptor (OTR), a promising new target for imaging, diagnosis and treatment of breast cancer. OTR is highly overexpressed in primary breast cancers, including metastatic and triple-negative cases, which remain difficult to treat. Our team has successfully developed potent, OTR-specific peptide tracers capable of visualising OTR in cells and tissues. Building on this progress, the project will refine and expand the design of these tracers and provide proof-of-concept data that they can be used to efficiently visualise and remove breast tumours.

Expected outcomes include theranostic tracers that can enhance breast tumour detection, support breast-conserving surgical tumour removal, and targeted radiotherapy, including subtypes that currently do not have targeted approaches. This combined approach of improved detection and targeted therapy has the scope to considerably enhance patient care, treatment options, and survival rates while reducing healthcare costs. The development of these tracers, supported by preclinical data and intellectual property protection, is expected to attract further investments and foster industry partnerships to accelerate clinical translation.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITAT WIEN
Net EU contribution
€ 150 000,00
Address
UNIVERSITATSRING 1
1010 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)